{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:23:29Z","timestamp":1793939009722,"version":"4.8.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T00:00:00Z","timestamp":1303776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s11934-011-0191-3","type":"journal-article","created":{"date-parts":[[2011,4,25]],"date-time":"2011-04-25T11:04:43Z","timestamp":1303729483000},"page":"274-277","source":"Crossref","is-referenced-by-count":31,"title":["Inflammation and Benign Prostatic Hyperplasia: Clinical Implications"],"prefix":"10.1007","volume":"12","author":[{"given":"Bilal","family":"Chughtai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Te","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,26]]},"reference":[{"issue":"5 Suppl","key":"191_CR1","first-page":"S122","volume":"12","author":"KT McVary","year":"2006","unstructured":"McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(5 Suppl):S122\u20138.","journal-title":"Am J Manag Care"},{"issue":"Suppl 3","key":"191_CR2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1464-410X.2008.07497.x","volume":"101","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101 Suppl 3:17\u201321.","journal-title":"BJU Int"},{"issue":"2","key":"191_CR3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1464-410X.2007.06910.x","volume":"100","author":"VC Mishra","year":"2007","unstructured":"Mishra VC et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int. 2007;100(2):327\u201331.","journal-title":"BJU Int"},{"issue":"1","key":"191_CR4","first-page":"1","volume":"1","author":"JC Nickel","year":"1994","unstructured":"Nickel JC. Prostatic inflammation in benign prostatic hyperplasia - the third component? Can J Urol. 1994;1(1):1\u20134.","journal-title":"Can J Urol"},{"issue":"1","key":"191_CR5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ucl.2007.09.012","volume":"35","author":"JC Nickel","year":"2008","unstructured":"Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35(1):109\u201315. vii.","journal-title":"Urol Clin North Am"},{"issue":"16","key":"191_CR6","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/pros.21027","volume":"69","author":"G Robert","year":"2009","unstructured":"\u2022\u2022 Robert, G., et al., Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate, 2009. 69(16): p. 1774\u201380. This study demonstrated a correlation between inflammation and clinically important parameters in patients with significant LUTS caused by BPH.","journal-title":"Prostate"},{"issue":"6","key":"191_CR7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2354.2008.01046.x","volume":"18","author":"ME McDowell","year":"2009","unstructured":"McDowell ME et al. A review of prostate-specific antigen screening prevalence and risk perceptions for first-degree relatives of men with prostate cancer. Eur J Cancer Care (Engl). 2009;18(6):545\u201355.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"3","key":"191_CR8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/pros.10238","volume":"56","author":"GE Steiner","year":"2003","unstructured":"Steiner GE et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003;56(3):171\u201382.","journal-title":"Prostate"},{"issue":"1","key":"191_CR9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/pros.20061","volume":"61","author":"W Wang","year":"2004","unstructured":"Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004;61(1):60\u201372.","journal-title":"Prostate"},{"issue":"2","key":"191_CR10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/jac\/46.2.157","volume":"46","author":"KG Naber","year":"2000","unstructured":"Naber KG, Weidner W. Chronic prostatitis-an infectious disease? J Antimicrob Chemother. 2000;46(2):157\u201361.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"191_CR11","first-page":"46","volume":"13","author":"LM Sugar","year":"2006","unstructured":"Sugar LM. Inflammation and prostate cancer. Can J Urol. 2006;13 Suppl 1:46\u20137.","journal-title":"Can J Urol"},{"issue":"2","key":"191_CR12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0302-2838(02)00548-1","volume":"43","author":"F Silverio Di","year":"2003","unstructured":"Di Silverio F et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43(2):164\u201375.","journal-title":"Eur Urol"},{"issue":"4","key":"191_CR13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.urology.2008.04.069","volume":"72","author":"S Falahatkar","year":"2008","unstructured":"\u2022\u2022 Falahatkar, S., et al., Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology, 2008. 72(4): p. 813\u20136. This study by demonstrated the possible role of anti-inflammatories in the progression of BPH. In addition, this trial showed a statistically significant decrease in nocturia in the celecoxib group.","journal-title":"Urology"},{"issue":"5","key":"191_CR14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/pros.20896","volume":"69","author":"G Penna","year":"2009","unstructured":"\u2022\u2022 Penna, G., et al., The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA\/Rho kinase and NF-kappaB pathways. Prostate, 2009. 69(5): p. 480\u201393. The authors were able to elucidate a pathway that eventually may be useful to decrease inflammation in those with clinically significant BPH.","journal-title":"Prostate"},{"issue":"12","key":"191_CR15","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.4049\/jimmunol.177.12.8504","volume":"177","author":"G Penna","year":"2006","unstructured":"Penna G et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol. 2006;177(12):8504\u201311.","journal-title":"J Immunol"},{"issue":"5","key":"191_CR16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0302-2838(03)00368-3","volume":"44","author":"R Vela Navarrete","year":"2003","unstructured":"Vela Navarrete R et al. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44(5):549\u201355.","journal-title":"Eur Urol"},{"issue":"2 Pt 1","key":"191_CR17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0022-5347(01)67064-2","volume":"154","author":"RB Nadler","year":"1995","unstructured":"Nadler RB et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2 Pt 1):407\u201313.","journal-title":"J Urol"},{"issue":"3 Pt 1","key":"191_CR18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.juro.2007.05.041","volume":"178","author":"JC Nickel","year":"2007","unstructured":"Nickel JC et al. Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol. 2007;178(3 Pt 1):896\u2013900. discussion 900\u20131.","journal-title":"J Urol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-011-0191-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-011-0191-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-011-0191-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:52:11Z","timestamp":1559436731000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-011-0191-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,26]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["191"],"URL":"https:\/\/doi.org\/10.1007\/s11934-011-0191-3","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,26]]}}}